SCHEMBL8570447

SCHEMBL8570447

FC(F)(F)CC1CCCCO1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.38
PDE8B O95263 2/20 0.35
PSEN1 P49768 2/20 0.34
PSEN2 P49810 2/20 0.34
APH1B Q8WW43 2/20 0.34
NCSTN Q92542 2/20 0.34
APH1A Q96BI3 2/20 0.34
PSENEN Q9NZ42 2/20 0.34
KMT2A Q03164 2/20 0.33
PKM P14618 1/20 0.33
HPGD P15428 2/20 0.33
HTT P42858 1/20 0.33
LMNA P02545 1/20 0.32
POLB P06746 1/20 0.32
TSHR P16473 1/20 0.32
USP2 O75604 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
ATM Q13315 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6304979 0.93 ALDH1A1 (0.42) ALDH1A1KMT2APKMHPGDLMNA
SCHEMBL28576575 0.85
SCHEMBL9408964 0.83 ALDH1A1 (0.36) ALDH1A1PDE8BKMT2APKMHPGD
SCHEMBL23465898 0.79 KMT2A (0.37) ALDH1A1PDE8BKMT2AHPGDHTT
SCHEMBL19193320 0.78 ALDH1A1 (0.36) ALDH1A1PDE8BPSEN1PSEN2APH1B
SCHEMBL18658933 0.78
SCHEMBL12705239 0.78
SCHEMBL23465899 0.78 ALDH1A1 (0.36) ALDH1A1PDE8BKMT2AHPGDHTT
SCHEMBL6985391 0.77 KMT2A (0.33) ALDH1A1PDE8BKMT2APKMHPGD
SCHEMBL8573737 0.77 KMT2A (0.33) ALDH1A1KMT2AHPGDHTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11667634-B2 Inhibitors of RAF kinases KINNATE BIOPHARMA INC. (US) 2023-06-06 US disclosed
CN-107849023-A Bicyclic lactams and methods of use thereof 豪夫迈·罗氏有限公司 2018-03-27 CN disclosed
EP-2723753-B1 SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF ALECTOS THERAPEUTICS INC (CA) 2017-08-02 EP disclosed
US-5744678-A NICKEL COMPOUND, ORGANOPHOSPHORUS COMPOUND, ORGANOALUMINUM COMPOUND, CARBON-HALOGEN COMPOUNDS; CATALYST SELECTIVITY NIPPON OIL CO., LTD. (JP) 1998-04-28 US disclosed
US-5728641-A Catalyst component for the polymerization of olefins NIPPON OIL COMPANY, LIMITED (JP) 1998-03-17 US disclosed
EP-0758563-A1 OLEFIN OLIGOMERIZATION CATALYST AND PROCESS FOR THE PREPARATION OF OLEFIN OLIGOMER USING IT NIPPON OIL COMPANY, LTD. (JP) 1997-02-19 EP disclosed
US-5556821-A Catalyst component for the polymerization of olefins NIPPON OIL COMPANY, LIMITED (JP) 1996-09-17 US disclosed
EP-0587440-A2 Catalyst component for the polymerisation of olefins and process for preparing olefin polymers using same NIPPON OIL COMPANY, LIMITED (JP) 1994-03-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11667634-B2 Inhibitors of RAF kinases BRAF, RAF1, NRAS ALDH1A1 3044/4885PDE8B 1892/4885PSEN1 4636/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.